Experienced in Neurofibromatosis Type 1 (NF1)

Dr. Ira J. Dunkel

Pediatric Hematology Oncology

1275 York Ave,

New York, NY

Clinical Trials:Currently Recruiting for 1 Trial

Experienced in Neurofibromatosis Type 1 (NF1)

1275 York Ave,

New York, NY

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ira Dunkel is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Dunkel is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Retinoblastoma, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Brain Stem Cancer.

His clinical research consists of co-authoring 145 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 1 clinical trial in the study of Neurofibromatosis Type 1 (NF1).

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Capital District Physicians Health

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

Locations

1275 York Ave, New York, NY 10021

Call: 212-639-2153

Additional Areas of Focus

Dr. Dunkel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life

Enrollment Status: Recruiting

Publish Date: April 16, 2025

Intervention Type: Behavioral

Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma

Enrollment Status: Active_not_recruiting

Publish Date: September 29, 2025

Intervention Type: Biological

Study Drug: APX005M

Study Phase: Phase 1

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Biological

Study Drug: HER2 Specific CAR T Cell

Study Phase: Phase 1

Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG

Enrollment Status: Active_not_recruiting

Publish Date: August 29, 2025

Intervention Type: Device, Combination product

Study Phase: Not Applicable

A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 1

A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3

Enrollment Status: Completed

Publish Date: July 23, 2025

Intervention Type: Drug

Study Drug: INCB7839

Study Phase: Phase 1

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Enrollment Status: Active_not_recruiting

Publish Date: June 26, 2025

Intervention Type: Procedure, Drug

Study Drug: Selumetinib

Study Phase: Phase 1/Phase 2

A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations

Enrollment Status: Active_not_recruiting

Publish Date: April 20, 2025

Intervention Type: Procedure, Drug

Study Drug: Savolitinib

Study Phase: Phase 1

Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: February 04, 2025

Intervention Type: Drug

Study Drugs: Dabrafenib, Trametinib, Hydroxychloroquine

Study Phase: Phase 1/Phase 2

A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma

Enrollment Status: Completed

Publish Date: January 13, 2025

Intervention Type: Drug, Radiation, Procedure, Biological

Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Thiotepa, Vincristine Sulfate

Study Phase: Phase 3

Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Enrollment Status: Completed

Publish Date: November 19, 2024

Intervention Type: Drug, Radiation

Study Phase: Phase 2

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

Enrollment Status: Active_not_recruiting

Publish Date: August 06, 2024

Intervention Type: Drug

Study Drugs: Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, Potassium Iodide, Dexamethasone, Antipyretic, Antihistamine, Anti-Emetics

Study Phase: Phase 2

Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Enrollment Status: Completed

Publish Date: April 25, 2024

Intervention Type: Drug

Study Drug: LBH589

Study Phase: Phase 1

A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors

Enrollment Status: Completed

Publish Date: August 27, 2021

Intervention Type: Other, Drug

Study Phase: Phase 1

Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

Enrollment Status: Terminated

Publish Date: March 02, 2021

Intervention Type: Other, Drug

Study Phase: Phase 1

Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma

Enrollment Status: Terminated

Publish Date: February 24, 2020

Intervention Type: Other, Biological

Study Phase: Phase 2

View 16 Less Clinical Trials

145 Total Publications

Detection and Characterization of RB1 Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test.

Journal: JAMA ophthalmology

Published: May 08, 2025

View All 145 Publications

Similar Doctors

Distinguished in Neurofibromatosis Type 1 (NF1)

Dr. John W. Glod

Pediatric Hematology Oncology

Distinguished in Neurofibromatosis Type 1 (NF1)

Dr. John W. Glod

Pediatric Hematology Oncology

195 Little Albany St,

New Brunswick, NJ

(31.8 miles away)

732-235-6455

Languages Spoken:

English

See accepted insurances

John Glod is a Pediatric Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Glod is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Neurofibromatosis Type 1 (NF1), Adult Soft Tissue Sarcoma, Neurofibromatosis, Brain Stem Cancer, and Thyroidectomy.

Advanced in Neurofibromatosis Type 1 (NF1)

Dr. Jeffrey Allen

Pediatric Hematology Oncology

Advanced in Neurofibromatosis Type 1 (NF1)

Dr. Jeffrey Allen

Pediatric Hematology Oncology

317 E 34th St, 8th Floor,

New York, NY

(1.7 miles away)

212-263-8400

Languages Spoken:

English

See accepted insurances

Jeffrey Allen is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Allen is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Neurofibromatosis, Glioma, Pineoblastoma, and Neurofibromatosis Type 1 (NF1).

Advanced in Neurofibromatosis Type 1 (NF1)

Dr. Sucharita Bhaumik

Pediatric Hematology Oncology

Advanced in Neurofibromatosis Type 1 (NF1)

Dr. Sucharita Bhaumik

Pediatric Hematology Oncology

120 Mineola Blvd, Suite 460,

Mineola, NY

(16.6 miles away)

516-663-9400

Languages Spoken:

English

See accepted insurances

Sucharita Bhaumik is a Pediatric Hematologist Oncology provider in Mineola, New York. Dr. Bhaumik is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Beta Thalassemia, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Malignant Peripheral Nerve Sheath Tumor.

VIEW MORE NEUROFIBROMATOSIS TYPE 1 (NF1) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dunkel's expertise for a condition

ConditionClose